| Drug General Information |
| Drug ID |
D01GFX
|
| Former ID |
DNC010680
|
| Drug Name |
OSI-906
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 3 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C26H23N5O
|
| InChI |
InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+
|
| InChIKey |
PKCDDUHJAFVJJB-VLZXCDOPSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
16743657, 23744765, 57275263, 74532058, 103749228, 103905463, 104150248, 131480754, 134347885, 135262588, 135626662, 136340263, 136350036, 136367290, 136367850, 137275876, 137553219, 137553254, 137553468, 144116323, 152258112, 152344419, 160646951, 162011565, 162038063, 162202653, 164041951, 170500763, 174531077, 177748835, 178103995, 180416100, 184816222, 189024767, 196408579, 198945656, 223704703, 226728959, 226729306, 226729307, 235565420, 241383573, 242533722, 242845726, 243364150, 244256025, 247345853, 252160378, 252215970, 252440138
|
| Target and Pathway |
| Target(s) |
Insulin-like growth factor I receptor |
Target Info |
Inhibitor |
[3]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Oocyte meiosis
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Long-term depression
|
|
Ovarian steroidogenesis
|
|
Progesterone-mediated oocyte maturation
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
SHP2 signaling
|
|
IGF1 pathway
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Integrins in angiogenesis
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
Reactome
|
IRS-related events triggered by IGF1R
|
|
SHC-related events triggered by IGF1R
|
|
WikiPathways
|
Senescence and Autophagy in Cancer
|
|
Insulin Signaling
|
|
Endochondral Ossification
|
|
Focal Adhesion
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Apoptosis
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00924989) A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7423). |
|---|
| REF 3 | Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5. Epub 2010 Mar 7.Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases. |
|---|
